

EUROPEAN
CURRICULUM VITAE
FORMAT

PERSONAL INFORMATION

Name **ARAGRI MARIANNA**
E-mail marianna.aragri@gmail.com
marianna.aragri@biologo.onb.it

Nationality Italian

WORK EXPERIENCE

- Dates (from – to) **SEPTEMBER 2011 → TODAY**
- Name and address of employer **University of Rome Tor Vergata**
• Type of business or sector **Department of Experimental Medicine and Surgery, Via Montpellier, 1 - 00133 Rome, Italy**
Head: Prof. Carlo Federico Perno
- Occupation or position held Temporary researcher in Molecular Virology
- Main activities and responsibilities Medical biologist

Diagnostic activities applied to the prevalent viral infections using techniques of molecular biology (Real-Time PCR, Sanger DNA Sequencing, Ultra-deep sequencing: Roche 454 System Junior; illumina MiSeq: training for MiSeq DX-RUO provided by ILLUMINA, INC, 23-24 May, at the Policlinico di RomaTor Vergata), immunofluorescence.

Research in the field of Antiviral Drug resistance in the management of Hepatitis C and B; HIV/AIDS epidemiology and drug resistance; Occult Hepatitis B; Hepatitis B reactivation in immunocompromised patients.

Genotypic and functional analysis of HIV-1,-2, HBV, HCV, BK and JCV proteins.
Bioinformatic analysis of nucleotidic sequences using SeqScape, ViroSeq, Sequencing Analysis, Bioedit, Clustal W softwares.
- Dates (from – to) **SEPTEMBER 2010 → JULY 2015**
- Name and address of employer **Tor Vergata University Hospital – Rome**
Head: Prof. Carlo Federico Perno
- Type of business or sector **Department of Laboratory Medicine, Section of Molecular Virology**
- Occupation or position held Training for the Medical School of Clinical Microbiology and Virology at Tor Vergata University, Rome
- Main activities and responsibilities Diagnostic activities applied to the prevalent viral infections using techniques of molecular biology (Real-Time PCR, Sanger DNA Sequencing, Ultra-deep sequencing), immunofluorescence.
- Dates (from – to) **SEPTEMBER 2009 → SEPTEMBER 2010**
- Name and address of employer **Centro Diagnostico Bisignano-Granata**
Type of business or sector **Via Santa Maria a Cubito n°155, 80019 Qualiano (NA)**
- Occupation or position held Head of lab
- Main activities and responsibilities Diagnostic activities applied to the biochemistry

- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Main activities and responsibilities

EDUCATION AND TRAINING

- Dates (from – to)
- Name and type of organisation providing education and training
 - Title of qualification awarded
- Dates (from – to)
- Name and type of organisation providing education and training
 - Title of qualification awarded
- Dates (from – to)
- Name and type of organisation providing education and training
 - Title of qualification awarded
- Dates (from – to)
- Name and type of organisation providing education and training
 - Title of qualification awarded

Technical skills and competencies

APRIL 2009 → AUGUST 2009

Santa Maria della Grazie Hospital – Pozzuoli, (NA)

Trainee biologist
Diagnostic activities, biochemistry

SEPTEMBER 2010-JULY 2015

Tor Vergata Hospital- Rome

Specialized School in Microbiology and Virology

SEPTEMBER 2007

Federico II- Napoli

Qualifying Examination for career as biologist

JULY 2007

Federico II University – Napoli

Degree in Biology

1999

Liceo Scientifico “Ettore Majorana”

High School Leaving Qualifications (scientific focus)

Virology field

Molecular biology: RT-PCR, gel electrophoresis, DNA/RNA purification and extraction, population sequencing with Sanger modified method.

Design, Set-up and Validation of home-made genotypic assay for sequencing of viral proteins (HBV, HCV, HIV, BKV, JCV) with Sanger sequencing using the genetic analyser ABI3130XL (Applied Biosystem).

Design, Set-up and Validation of home-made assay for pyrosequencing using the instrument Roche 454 System Junior; illumina MiSeq.

Execution and interpretation of REAL-TIME PCR for HIV, HBV, HCV quantification using the technology Cobas AmpliPrep-Cobas TaqMan (Roche) and the Abbott m2000 RealTime System.

DNA/RNA extraction using the instrument QIASymphony SP instrument (Quiagen).

Analysis for the detection and quantification of viral protein with diagnostic applications.

Adenovirus, EBV, JC, BK, Enterovirus, PB19, HSV-1, HSV-2, CMV, HIV1/2, HBV, HCV, Flu virusi, RSV, VZV e HPV, using the instrument Applied Biosystem 7300 e 7500, Smart Cycler, Pyro (Qiagen), EasyQ, Qiacube, Easymag, Qiasymphony, COBAS AmpliPrep/COBAS Taqman, m2000 Abbott, CFX9600 Biorad, Light Cycler v2.0 Roche.

Manipulation of different types of viruses (HIV, HSV, Influenza) in Biosafety-Level-3 Laboratory. Optical and Fluorescence microscopy use.

Microbiology field

Volunteer as a Biologist, at the Policlinico di Roma Tor Vergata, Department of Laboratory Medicine, Unit of Microbiology and Clinical Virology. Acquisition of operative protocols for the processing of different biological samples (blood cultures, urinoculture, coproculture, respiratory materials, intraoperative materials, soft tissues and serous cavities, urogenital samples) by setting up direct cultures on liquid and / or solid, selective or enriching medium. Sowing of colony on plate. Use of the light microscope (Gram stain, methylene blue and Ziel-Nielsen). Reading and interpretation of solid ground plates.

Bioinformatics field

Very good knowledge of Office, scientific databases (homemade and internet sources) and programs for data analysis (statistical [SPSS, R], sequence analysis [SeqScape, Bioedit], mutation analysis, phylogenesis analysis [Mega].

Publications:

First Author of 1, and Co-author of 17, scientific papers, published in International journals.

First Author of 11, and Co-author of 78, posters or oral presentations (with 6 personal oral communications), at National and International Conferences.

The main issues of the papers are: Antiviral Drug resistance in the management of Hepatitis C and Hepatitis B;

SCNTIFIC PUBLICATIONS

1. "Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression"

Salpini R, Colagrossi L, Bellocchi MC, Surdo M, Becker C, Alteri C, Aragri M, Ricciardi A, Armenia D, Pollicita M, Di Santo F, Carioti L, Louzoun Y, Mastroianni CM, Lichtner M, Paoloni M, Esposito M, D'Amore C, Marrone A, Marignani M, Sarrecchia C, Sarmati L, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V.. *Hepatology*. 2015 Mar;61(3):823-33. Epub 2015 Jan 28. IF 11.19

2. "Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection"

Mirabelli C, Surdo M, Van Hemert F, Lian Z, Salpini R, Cento V, Cortese MF, Aragri M, Pollicita M, Alteri C, Bertoli A, Berkhout B, Micheli V, Gubertini G, Santoro MM, Romano S, Visca M, Bernassola M, Longo R, De Sanctis GM, Trimoulet P, Fleury H, Marino N, Mazzotta F, Cappiello G, Spanò A, Sarrecchia C, Zhang JM, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V.. *J Infect*. 2015 Mar;70(3):288-98. Epub 2014 Nov 6 IF 4.07

3. "Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome"

Cento V, Di Paolo D, Di Carlo D, Micheli V, Tontodonati M, De Leonardis F, Aragri M, Antonucci FP, Di Maio VC, Mancon A, Lenci I, Manunta A, Taliani G, Di Biagio A, Nicolini LA, Nosotti L, Sarrecchia C, Siciliano M, Landonio S, Pellicelli A, Gasbarrini A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F.. *Dig Liver Dis*. 2015 Feb;47(2):157-63. doi: 10.1016/j.dld.2014.11.010. Epub 2014 Nov 24.

4. "Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents"

Ceccherini Silberstein F, Di Maio VC, Aragri M, Ciotti M, Cento V, Perno CF,.. *Hepatology*. 2015 May 14. doi: 10.1002/hep.27895.

5. "A Recent epidemiological-cluster of acute hepatitis B genotype F1b infection in a restricted Geographic area of Italy"

Pollicita M, Alteri C, Bellocchi MC, Armenia D, Carioti L, Salpini R, Colagrossi L, Battisti A, Aragri M, Fabeni L, Mariani R, Dalessandro M, Ranelli A, Paoloni M, Parruti G, Perno CF, Svicher V.. *Clin Microbiol Infect*. 2015 Aug 7. pii: S1198-743X(15)00783-1. doi: 10.1016/j.cmi.2015.07.022. [Epub ahead of print]. IF 5.77

6. "HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels"

Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marengo S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group.. *J Antimicrob Chemother*. 2015 Dec 17. pii: dkv403. [Epub ahead of print]

7. “Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B”

Marianna Aragri*, Claudia Alteri, Arianna Battisti, Domenico Di Carlo, Carmine Minichini, Caterina Sagnelli, Maria Concetta Bellocchi, Maria Antonietta Pisaturo, Mario Starace, Daniele Armenia, Luca Carioti, Michela Pollicita, Romina Salpini, Evangelista Sagnelli, Carlo Federico Perno, Nicola Coppola§, Valentina Svicher§Multiple HBV The Journal of Infectious Diseases, 2016 Feb 9. pii: jiw049. [Epub ahead of print].

8. “Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district”

Polilli E, Cento V, Restelli U, Ceccherini-Silberstein F, Aragri M, Di Maio VC, Sciacca A, Santoleri F, Fazii P, Costantini A, Perno CF, Parruti G. Clinicoecon Outcomes Res. 2016 Sep 14;8:467-473.

9. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.

Velia Chiara Di Maio , Valeria Cento , Ilaria Lenci , Marianna Aragri , Piera Rossi , Silvia Barbaliscia , Michela Melis , Gabriella Verucchi , Carlo Federico Magni , Elisabetta Teti , Ada Bertoli , Francesco Paolo Antonucci , Maria Concetta Bellocchi , Valeria Micheli , Chiara Masetti , Simona Landonio , Simona Francioso , Francesco Santopaolo , Adriano Pellicelli , Vincenza Calvaruso , Laura Gianserra, Massimo Siciliano, Dante Romagnoli, Raffaele Cozzolongo , Antonio Grieco, Jacopo Vecchiet, Filomena Morisco, Manuela Merli, Giuseppina Brancaccio , Antonio Di Biagio, Elisabetta Loggi, Claudio Maria Mastroianni, Valeria Pace Palitti , Pierluigi Tarquini, Massimo Puoti, Gloria Taliani, Loredana Sarmati , Antonino Picciotto , Vincenzo Vullo, Nicola Caporaso, Maurizio Paoloni, Caterina Pasquazzi, Giuliano Rizzardini , Giustino Parruti, Antonio Craxi , Sergio Babudieri , Massimo Andreoni , Mario Angelico , Carlo Federico Perno , Francesca Ceccherini-Silberstein* for the HCV Italian Resistance Network Study Group †Accepted Clinical Gastroenterology and Hepatology

10. “Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy”

Cuyper L, Vrancken B, Fabeni L, Marascio N, Cento V, Di Maio VC, Aragri M, Pineda-Peña AC, Schrooten Y, Van Laethem K, Balog D, Focà A, Torti C, Nevens F, Perno CF, Vandamme AM, Ceccherini-Silberstein F.

BMC Evol Biol. 2017 Mar 7;17(1):70. doi: 10.1186/s12862-017-0913-3.

11. “Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation”

Lenci I, Bosa A, Milana M, Baiocchi L, Antonucci FP, Aragri M, Ceccherini-Silberstein F, Perno CF, Tisone G, Angelico M. Accepted May 2017, Digestive Diseases and Sciences

12. “Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study”

Cento, Valeria; Aragri, Marianna; Teti, Elisabetta; Polilli, Ennio; Bertoli, Ada; Foroghi, Luca; Barbaliscia, Silvia; Di Maio, Velia Chiara; Pieri, Alessandro; Pace Palitti, Valeria; Sarmati, Loredana; Parruti, Giustino; Andreoni, Massimo; Perno, Carlo-Federico; Ceccherini-Silberstein, Francesca. Accepted Journal of Antimicrobial Chemotherapy, Jul-2017

13.” Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens?”

Velia Chiara Di Maio, Valeria Cento, Marianna Aragri, Stefania Paolucci, Teresa Pollicino, Nicola Coppola, Bianca Bruzzone, Valeria Ghisetti, Maurizio Zazzi, Maurizia Brunetto, Ada Bertoli, Silvia Barbaliscia, Silvia Galli, William Gennari, Fausto Baldanti, Giovanni Raimondo, Carlo Federico Perno, Francesca

Ceccherini-Silberstein, on behalf of treatment team of the HCV Virology Italian Resistance Network (VIRONET-C), Accepted Journal of Hepatology, Sep-2017

14. “Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life”

Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni CF, Paolucci S, Babudieri S, Siciliano M, Pasquazzi C, Ciancio A, Perno CF, Ceccherini-Silberstein F; HCV retreatment team VIRONET-C study group. Collaborators Micheli V, Troshina Y, Biliotti E, Milana M, Melis M, Teti E, Lambiasi L, Menzaghi B, Nicolini LA, Marengo S, Di Maio VC, Aragri M, Pecchioli A, Bertoli A, Sarrecchia C, Macera M, Coppola N, Puoti M, Romagnoli D, Pellicelli A, Bonora S, Novati S, Baldanti F, Ghisetti V, Andreoni M, Taliani G, Rizzardini G, Angelico M.

Clin Microbiol Infect. 2017

12. "Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study"

Cento, Valeria; Aragri, Marianna; Teti, Elisabetta; Polilli, Ennio; Bertoli, Ada; Foroghi, Luca; Barbaliscia, Silvia; Di Maio, Velia Chiara; Pieri, Alessandro; Pace Palitti, Valeria; Sarmati, Loredana; Parruti, Giustino; Andreoni, Massimo; Perno, Carlo-Federico; Ceccherini-Silberstein, Francesca. Accepted Journal of Antimicrobial Chemotherapy, Jul-2017

13. "Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens?"

Velia Chiara Di Maio, Valeria Cento, Marianna Aragri, Stefania Paolucci, Teresa Pollicino, Nicola Coppola, Bianca Bruzzone, Valeria Ghisetti, Maurizio Zazzi, Maurizia Brunetto, Ada Bertoli, Silvia Barbaliscia, Silvia Galli, William Gennari, Fausto Baldanti, Giovanni Raimondo, Carlo Federico Perno, Francesca

Ceccherini-Silberstein, on behalf of treatment team of the HCV Virology Italian Resistance Network (VIRONET-C), Accepted Journal of Hepatology, Sep-2017

14. "Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life"

Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni CF, Paolucci S, Babudieri S, Siciliano M, Pasquazzi C, Ciancio A, Perno CF, Ceccherini-Silberstein F; HCV retreatment team VIRONET-C study group.

Collaborators

Micheli V, Troshina Y, Biliotti E, Milana M, Melis M, Teti E, Lambiase L, Menzaghi B, Nicolini LA, Marengo S, Di Maio VC, Aragri M, Pecchioli A, Bertoli A, Sarrecchia C, Macera M, Coppola N, Puoti M, Romagnoli D, Pellicelli A, Bonora S, Novati S, Baldanti F, Ghisetti V, Andreoni M, Taliani G, Rizzardini G, Angelico M.

Clin Microbiol Infect. 2017

15. "HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals."

Guardigni V, Cento V, Ianniruberto S, Badia L, Aragri M, Conti M, Perno CF, Viale P, Ceccherini-Silberstein F, Verucchi G.

Infection. 2018 May 26.

16. "Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy."

Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxi A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C).

Sci Rep. 2018 Jun 12

17. "Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis."

Ciardi MR, Iannetta M, Zingaropoli MA, Salpini R, Aragri M, Annecca R, Pontecorvo S, Altieri M, Russo G, Svicher V, Mastroianni CM, Vullo V.

Open Forum Infect Dis. 2018 Dec 26.

18. "Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report."

Foroghi Biland L, Ferrari L, Malagnino V, Teti E, Cerva C, Gentile A, Aragri M, Salpini R, Svicher V, Andreoni M, Sarmati L.

J Med Case Rep. 2019 Sep 22;13(1):299. doi: 10.1186/s13256-019-2232-3.

19. "Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation"

Salpini R, Pietrobattista A, Piermatteo L, Basso MS, Bellocchi MC, Liccardo D, Carioti L, Francalanci P, Aragri M, Alkhatib M, Scutari R, Candusso M, Ciotti M, Svicher V. J Infect Dis. 2019 Nov 6;220(12):1935-1939. doi: 10.1093/infdis/jiz411.

20. "NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients"

Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxi A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F.

Cells. 2019 Jul 2;8(7):666. doi: 10.3390/cells8070666

21. "A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro"

Salpini R, Piermatteo L, Battisti A, Colagrossi L, Aragri M, Yu La Rosa K, Bertoli A, Saccomandi P, Lichtner M, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Iapadre N, Cerva C, Aquaro S, Angelico M, Sarmati L, Andreoni M, Verheyen J, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V.
Viruses. 2020 Feb 23;12(2):251. doi: 10.3390/v12020251.

22. "Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance"

Aragri M, Milana M, Di Maio VC, Lenci I, Carioti L, Perno CF, Svicher V, Angelico M, Ceccherini-Silberstein F.
Clin Microbiol Infect. 2020 Sep;26(9):1266-1268. doi: 10.1016/j.cmi.2020.03.022. Epub 2020 Mar 30.

23. "Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen"

de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C).
J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358. doi: 10.1093/jac/dkaa304.

24. "Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C"

Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxi A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C).
Liver Int. 2021 Aug;41(8):1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8.

25. "Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy"

Mazucco W, Chiara di Maio V, Bronte F, Fabeni L, Pipitone RM, Grimaudo S, Ferraro D, Marotta C, Aragri M, Macaluso M, Vitale F, Di Raimondo F, Ceccherini-Silberstein F, Di Marco V. J Hosp Infect. 2021 Sep;115:51-58. doi: 10.1016/j.jhin.2021.06.007. Epub 2021 Jun 23

Invited Speaker in:

1. "Epatite C e comorbidità: l'importanza di un approccio multidisciplinare" on 23 september 2016, Policlinico Universitario di Germaneto, Università di Catanzaro, Viale Europa Loc. Germaneto, 88100 Catanzaro.
2. "HOT TOPICS IN GASTROENTEROLOGIA 2016", on 25-26 november 2016, Facoltà di Medicina e Chirurgia dell'Università Politecnica delle Marche (Ancona).
3. "Tailored therapy nel paziente con infezione da HCV" on 12 July 2017, Hotel A.Roma Lifestyle, Giorgio Zoega 59, Roma.
4. Progetto Educazionale Nazionale ECHO in HCV "La gestione dei dati di laboratorio nella pratica clinica - Focus su genotipizzazione e resistenza in HCV" on 21, 22 november 2017, Università degli Studi di Roma "Tor Vergata".
5. Progetto Educazionale Nazionale ECHO in HCV "La gestione dei dati di laboratorio nella pratica clinica - Focus su genotipizzazione e resistenza in HCV" on 25, 26 January 2018 Università degli Studi di Roma "Tor Vergata".
6. Progetto Educazionale Nazionale ECHO in HCV "La gestione dei dati di laboratorio nella pratica clinica - Focus su genotipizzazione e resistenza in HCV" on 17, 18 April 2018 Università degli Studi di Roma "Tor Vergata".
7. "Laboratorio di Epatologia, Policlinico Tor Vergata (LEP-PTV)", 9 Febbraio 2018. Aula ECM - Policlinico Tor Vergata - Viale Oxford, 81-Roma.
8. 12th Annual Liver Meeting "What is new in Clinical Hepatology in 2018?" on 21 September 2018, Aula Anfiteatro – Università degli Studi di Roma Tor Vergata.

Prizes and awards

Young investigator bursary at the EASL International Liver Congress 2014 – The 49nd annual meeting of the European Association for the Study of the Liver (EASL), London, 09-13 April 2014

Young investigator bursary at the EASL International Liver Congress 2015 – The 50nd annual meeting of the European Association for the Study of the Liver (EASL), Wien, 22-26 April 2015

Young investigator bursary at the EASL International Liver Congress 2016 – The 51nd annual meeting of the European Association for the Study of the Liver (EASL), Barcelona, 13-17 April 2016

Best Poster at the 14th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 2016, Rome

“In compliance with the Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance to art. 7 of the above mentioned decree.”

Roma, 29/07/2022

Marianna Aragri

